{
    "clinical_study": {
        "@rank": "57151", 
        "arm_group": [
            {
                "arm_group_label": "CLP 15 g QD", 
                "arm_group_type": "Experimental", 
                "description": "Cross-Linked Polyelectrolyte (CLP) study medication delivered immediately before bedtime"
            }, 
            {
                "arm_group_label": "CLP 7.5 g BID", 
                "arm_group_type": "Experimental", 
                "description": "Cross-Linked Polyelectrolyte (CLP) Study medication delivered b.i.d. one hour before breakfast and dinner"
            }, 
            {
                "arm_group_label": "CLP 5 g TID", 
                "arm_group_type": "Experimental", 
                "description": "Cross-Linked Polyelectrolyte (CLP) Study medication delivered t.i.d. one hour before breakfast, lunch and dinner"
            }, 
            {
                "arm_group_label": "CLP 3.75 g QID", 
                "arm_group_type": "Experimental", 
                "description": "Cross-Linked Polyelectrolyte (CLP) Study medication delivered q.i.d on hour before breakfast, lunch, dinner and immediately before bedtime"
            }
        ], 
        "brief_summary": {
            "textblock": "This is a study to determine the effect of four different dosing regimens of CLP in normal\n      healthy volunteers."
        }, 
        "brief_title": "Evaluation of Four Different Dosing Regimens of Cross-Linked Polyelectrolyte (CLP) in Healthy Volunteers", 
        "condition": "Healthy", 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Healthy volunteer is \u2265 18 years of age with BMI of 18-32\n\n          -  Females could not be pregnant or breast feeding and had to be using birth control\n\n          -  Must have regular bowel habits, typically producing at least 1 daily bowel movement\n\n        Exclusion Criteria:\n\n          -  Screening 12-lead ECG demonstrating QTc interval >430 msec for males and >450 msec\n             for females, or any cardiac rhythm disorder considered by the Investigator to be\n             clinically relevant\n\n          -  History or presence of gastrointestinal conditions\n\n          -  Positive drug screen for substances of abuse\n\n          -  Positive results for HIV, hepatitis B, or hepatitis C"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "Accepts Healthy Volunteers", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "25", 
            "@type": "Actual"
        }, 
        "firstreceived_date": "March 3, 2014", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02079233", 
            "org_study_id": "CTST-16"
        }, 
        "intervention": {
            "arm_group_label": [
                "CLP 15 g QD", 
                "CLP 7.5 g BID", 
                "CLP 5 g TID", 
                "CLP 3.75 g QID"
            ], 
            "description": "CLP was administered orally, in capsules, for 7 consecutive days.", 
            "intervention_name": "Cross-Linked Polyelectrolyte (CLP)", 
            "intervention_type": "Drug"
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "No", 
        "keyword": [
            "Basic Science", 
            "Safety", 
            "Tolerability", 
            "Efficacy of CLP"
        ], 
        "lastchanged_date": "March 4, 2014", 
        "number_of_arms": "4", 
        "official_title": "Phase 1 Multiple Dose Trial to Assess the Safety, Tolerability and Efficacy of Four Different Dosing Regimens of Cross-Linked Polyelectrolyte (CLP) in Healthy Volunteers", 
        "overall_official": {
            "affiliation": "Jasper Clinic, Inc.", 
            "last_name": "Shanthini A. Daniel, MD", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 1", 
        "primary_completion_date": {
            "#text": "July 2010", 
            "@type": "Actual"
        }, 
        "primary_outcome": {
            "description": "The primary endpoint was sodium removal from the stool compared between the Baseline period and the Treatment Period.", 
            "measure": "Change in fecal sodium content", 
            "safety_issue": "No", 
            "time_frame": "Baseline (Days 3-6) vs. Treatment (Days 10-13)"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02079233"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "source": "Sorbent Therapeutics", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Sorbent Therapeutics", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "May 2010", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "March 2014"
    }
}